Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / UCHL1

UCHL1

Basics

Aliases:
This biomarker is also known as:
  • PGP 9.5,
  • UCH-L1,
  • ubiquitin C-terminal hydrolase,
  • Neuron cytoplasmic protein 9.5,
  • PARK5,
  • PGP95,
  • ubiquitin carboxyl-terminal hydrolase isozyme L1,
  • Ubiquitin thioesterase L1,
  • ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase),
  • Uch-L1,
  • PGP9.5,

View in BioMuta

Description…

PGP9.5, also called Ubiquitin-protein hydrolase (UCHL1), is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer. Expression of UCHL1 is highly specific to neurons and to cells of the diffuse neuroendocrine system and their tumors. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Oxidation of Met-1, Met-6, Met-12, Met-124 and Met-179 to methionine sulfoxide, and oxidation of Cys-220 to cysteine sulfonic acid have been observed in brains from Alzheimer disease (AD) and Parkinson disease (PD) patients. PGP9.5 has been proposed as a marker with a potential role in carcinogenesis.

Attributes

QA State: Accepted
Type: Protein
Short Name:

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Three
QA State: Under Review

Overview

PGP9.5 antigens were found to be targets of autoantibodies in newly diagnosed subjects with lung cancer. PGP9.5 is also highly expressed in non-small lung cancer cell line H157, having high invasive potential, and the expression of PGP9.5 in tumor cells enhances their invasive potential in vitro and in vivo.

Performance Comment

The findings of this study show autoantibodies to UCHL1 (PGP9.5) may have diagnostic utility in conjunction with an imaging modality in symptomatic patients.

Supporting Study Data

The following studies/protocols provide evidence supporting UCHL1 indications for the Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 44.0 51.0 N/A N/A N/A
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 82.0 26.0 N/A N/A N/A
Decision Rule

PMID:18794547

Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Studies

No associated studies or protocols found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement